Skip to main content

Table 2 Current LTP and STP treatment by country

From: Clinical characteristics and burden of illness in patients with hereditary angioedema: findings from a multinational patient survey

Treatment,a n (%) AU
(n = 28)
AT
(n = 13)
CA
(n = 32)
FR
(n = 58)
DE
(n = 7)
ES
(n = 39)
CH
(n = 8)
UK
(n = 57)
LTP n = 22 n = 2 n = 23 n = 35 n = 1 n = 28 n = 2 n = 38
Cinryze® (C1 esterase inhibitor [human]) 1 (50.0) 4 (17.4) 7 (20.0) 1 (100.0) 1 (3.6) 8 (21.1)
Berinert® (C1 esterase inhibitor [human]) 10 (45.5) 16 (69.6) 2 (5.7) 7 (25.0) 1 (50.0) 13 (34.2)
Lysteda® (tranexamic acid) 3 (13.0) 2 (5.7) 2 (7.1) 12 (31.6)
Tranexamic acid 8 (36.4)
Azol®/danazol 9 (40.9) 1 (4.3) 15 (42.9) 11 (39.3) 7 (18.4)
Winstrol® (stanozolol) 10 (35.7) 1 (2.6)
Oxandrin® (oxandrolone) 1 (2.6)
Other 1 (50.0) 3 (13.0) 15 (42.9) 1 (3.6) 1 (50.0) 4 (10.5)
STP n = 18 n = 8 n = 21 n = 30b n = 6 n = 30 n = 4 n = 39
Cinryze® (C1 esterase inhibitor [human]) 1 (5.6) 2 (25.0) 2 (9.5) 4 (13.3) 1 (16.7) 5 (16.7) 7 (17.9)
Berinert® (C1 esterase inhibitor [human]) 13 (72.2) 6 (75.0) 18 (85.7) 11 (36.7) 5 (83.3) 19 (63.3) 4 (100.0) 28 (71.8)
Lysteda® (tranexamic acid) 2 (9.5) 1 (3.3) 1 (3.3) 3 (7.7)
Tranexamic acid 1 (5.6)
Azol®/danazol 6 (33.3) 1 (4.8) 13 (43.3) 8 (26.7) 3 (7.7)
Winstrol® (stanozolol) 4 (13.3)
Other 2 (11.1)
  1. AU Australia, AT Austria, CA Canada, CH Switzerland, DE Germany, ES Spain, FR France, LTP long-term prophylaxis, STP short-term prophylaxis, UK United Kingdom
  2. aPatients could select > 1 treatment
  3. bMissing data for 1 patient